Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881218 · ClinicalTrials.gov registry record · Early Phase 1
Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
A Early Phase 1 study of Ischemic Heart Disease, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00881218: Completed Early Phase 1 study of Ischemic Heart Disease, sponsored by Washington University School of Medicine.
NCT00881218 is a Early Phase 1 study of Ischemic Heart Disease that has completed, run by Washington University School of Medicine. The registered enrollment target is 50 participants, below the 263-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00881218, a Early Phase 1 study of Ischemic Heart Disease, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to determine whether the drug regadenoson can be used during magnetic resonance imaging to assess regions of poor blood flow to the heart. The hypothesis of this study is that a single injection of regadenoson could be used instead of a standard adenosine infusion to produce coronary vasodilatation and demonstrate myocardial ischemia during first-pass perfusion cardiac MRI.
Conditions Studied
Interventions
- DRUG Regadenoson
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-12 |
| Phase | Early Phase 1 |
What the finished NCT00881218 record still lists
NCT00881218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 263-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Ischemic Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Regadenoson is the first listed.
NCT00881218 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00881218 about?
NCT00881218 is a clinical study titled "Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson". This is a pilot study to determine whether the drug regadenoson can be used during magnetic resonance imaging to assess regions of poor blood flow to the heart. The hypothesis of this study is that a single injection of regadenoson could be used instead of a standard adenosine infusion to produce c...
What is the current status of trial NCT00881218?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2009-06. Estimated completion is 2011-12.
What conditions does trial NCT00881218 study?
This clinical trial studies the following conditions: Ischemic Heart Disease.
What interventions are being tested in trial NCT00881218?
The interventions under investigation include: Regadenoson (DRUG).
Who is sponsoring clinical trial NCT00881218?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00881218 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00881218's enrollment target sits among peer trials
50 11th of 14 higher than 4 of 14 other Ischemic Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
RECRUITING · NA
-
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy
RECRUITING · Phase 2
-
Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease
RECRUITING · NA
-
Development of CIRC Technologies
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia